Chennai, India Mar 17th: Agilisium, a leading Life Sciences domain-native AI services company, today announced a INR 50 Crore investment — close to US$ 5.5 million — to fundamentally transform how pharmaceutical, biotech, and medtech enterprises operationalize AI. At the heart of this initiative is the development and deployment of FDX, Forward Deployment Experts, a new professional standard defined by Agilisium built across four dimensions: Domain, AI & Technology, Consultative Solutioning, and Systems & Process Thinking.
Unlike traditional AI services, FDX professionals are embedded directly inside Life Sciences organizations working alongside scientific, regulatory, and commercial teams not advising from the outside but driving transformation from within. The investment will reskill and deploy Agilisium‘s global workforce of more than 1,000 professionals as embedded AI transformation partners, making this the world’s first forward deployment experts built exclusively for Life Sciences.
The announcement arrives at an inflection point. Life Sciences organizations worldwide are accelerating adoption of context-aware agentic AI across drug discovery, clinical trials, pharmacovigilance, regulatory operations, and commercial operations yet most enterprise AI initiatives stall not because the technology fails, but because the talent required to operationalize it does not exist at scale.
Mr Raj Babu, Founder and CEO, Agilisium, said, “The biggest constraint in AI adoption in Life Sciences is no longer technology; it is talent. The companies that will lead Life Sciences in the next decade will not be the ones that simply purchase AI models. They will be the ones that embed AI capability deep inside their organizations. At Agilisium, our advantage comes from the compounding institutional and domain knowledge we have built by focusing exclusively on Life Sciences.”
“Our FDX team is crucial to staying ahead of the curve and delivering innovative solutions for our clients. By integrating AI, innovation, and execution, we are building an operating model that translates intelligence into real-world impact at scale.” Mr Arunkumar Arjunan, Chief Operating Officer & Chief AI & Innovation Officer, Agilisium.
“Building the FDX standard is about creating real value for our clients by combining AI literacy, deep domain understanding, and a strong focus on measurable outcomes. This is not an upskilling talent but a fundamental transformation.” Ms. Hemapriya Dharshini, Senior Vice President, Agilisium
“Building capabilities at the intersection of domain, technology, and AI-driven systems are fundamental to scaling AI in Life Sciences. The FDX standard is designed to develop professionals who can seamlessly bridge these areas and drive sustained transformation across the value chain.” Mr. Venkatesa Prasad Neelamegam, Chief Capabilities Officer, Agilisium
A New Operating Model for AI-Enabled Life Sciences
Unlike traditional consulting model, Agilisium’s forward–deployment model combines deep Life Sciences domain expertise with AI engineering and data science capability and then keeps both inside the client’s organization for the duration of the transformation. Agilisium professionals sit beside scientists, clinical teams, regulatory leaders, and commercial stakeholders, designing, deploying, and continuously operating AI-driven capabilities rather than handing them over.
This approach is designed to move Life Sciences enterprises beyond the pilot trap, the persistent cycle of proof-of-concepts that demonstrate value but never reach production scale. The forward–deployment model stakes Agilisium’s commercial success on whether the AI works inside the client’s environment, not on whether the engagement was delivered.
Three Offerings. One Integrated Model.
To operationalize the forward deployment model, Agilisium introduced three integrated service offerings anchored by FDX:
FDX — Forward Deployment Experts
Senior practitioners who sit inside a client’s organization are not offsite in a consulting office and rebuild scientific, regulatory, and commercial workflows with AI at their core. FDX is a new professional standard defined by expertise across four intersecting dimensions: Domain, AI & Technology, Consultative Solutioning, and Systems & Process Thinking. These are not project managers or advisors; they are multi-dimensional experts who own outcomes.
FDA — Forward–Deployment Agents
Autonomous AI agents trained each enterprise’s proprietary data, regulatory frameworks, and operational logic not generic foundation models adapted from the outside. These agents are context-centric by design, built to operate within the specific compliance and scientific environment of each client.
FDS — Forward–Deployment Services
Managed teams that remain embedded after initial deployment continuously running, optimizing, and evolving AI capabilities through every model lifecycle. Clients do not inherit technical debt when the engagement closes; they inherit a functioning, improving system.
Together, FDX, FDA, and FDS are designed to close the gap between AI experimentation and AI at scale across the full drug development and commercialization lifecycle.
Addressing the Life Sciences AI Talent Gap
Across the industry, organizations face a growing shortage of professionals who combine deep domain expertise with AI engineering capability and regulatory awareness. The problem is not a shortage of AI engineers, nor a shortage of life scientists; it is a shortage of professionals who are both, and who understand how to operate within the highly regulated, data-sensitive environment that Life Sciences demands. Agilisium’s FDX standard is purpose-built to fill this gap.
Agilisium’s INR 50 crore workforce transformation initiative will fund structured training, domain capability development, and immersive client engagement models designed to develop and certify professionals to the FDX standard. The company has built its competitive position by focusing exclusively on Life Sciences for over a decade, a compounding institutional advantage it now intends to scale systematically across its workforce.
